Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Demineralized Dentin Graft (DDG) is an autogenous biomaterial used for bone regeneration, specifically in alveolar ridge preservation (ARP) following tooth extraction. Developed and studied by researchers at Ain Shams University, the graft is prepared from the patient's own extracted teeth. The dentin is processed and demineralized to expose the organic matrix and endogenous growth factors, such as Bone Morphogenetic Proteins (BMPs), which facilitate osteoinduction and osteoconduction. This material serves as a scaffold to minimize alveolar ridge resorption and maintain bone volume for subsequent dental implant placement. Clinical trials at Ain Shams University have specifically evaluated the influence of different healing intervals (12, 18, and 24 weeks) on the efficacy of the graft in maintaining hard and soft tissue volume.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Demineralized Dentin Graft.